DWP450 for Treating Moderate to Severe Glabellar Lines
A Multi-center, Randomized, Double-blind, Positive Drug-controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
Sponsor: Daewoong Pharmaceutical Co. LTD.
A PHASE3 clinical study on Moderate to Severe Glabellar Lines, this trial is completed. The trial is conducted by Daewoong Pharmaceutical Co. LTD. and has accumulated 3 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE3
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daewoong Pharmaceutical Co. LTD.
For direct contact, visit the study record on ClinicalTrials.gov .